PCH
TVTX icon

Polar Capital Holdings’s Travere Therapeutics TVTX Stock Holding History

Polar Capital Holdings’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-125,000
Closed -$3.41M – 354
2020
Q4 		$3.41M Buy
+125,000
New +$2.92M 0.02% 269

Other funds holding TVTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Polar Capital Holdings's TVTX Position: Q1 2021 in Review

Polar Capital Holdings sold out of Travere Therapeutics (TVTX) in Q1 2021, closing a stake of 125,000 shares — an estimated $3.41M sold.

Polar Capital Holdings first reported a position in TVTX in Q4 2020 and held it in 1 quarter. The position peaked at $3.41M in Q4 2020. 150 funds tracked by Wall St. Rank hold TVTX as of Q1 2021.

  • Polar Capital Holdings reported no remaining Travere Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Polar Capital Holdings sold 125,000 Travere Therapeutics shares in Q1 2021, an estimated $3.41M.
  • Polar Capital Holdings first reported a position in Travere Therapeutics in Q4 2020 and held it in 1 quarter.
  • Polar Capital Holdings's Travere Therapeutics position peaked at $3.41M in Q4 2020.
  • 150 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2021.

Based on Polar Capital Holdings's 13F filing for Q1 2021, filed 17 May 2021.